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Methods: From November 2007 to December 2011, 384 patients underwent TAVI in our
center [233 Edwards and 151 CoreValve]. 74 were treated with post dilatation for residual
AR following valve implantation. In this study, 68 were analyzed after excluding 6
patients due to unavailable data.
Results: Mean age was 796.2 yrs. Male gender was 42 (61.7%). Mean logistic
Euroscore and STS score were 25.217.3 and 9.19.1, respectively. Mean grades of
aortic regurgitation at baseline, before and after post dilatation were 1.31.1, 2.30.7 and
0.80.6, respectively. CT scan analysis showed annular coronal diameter 262mm,
sagittal diameter 223mm, mid-sinusal diameter 364mm, sinus-tubular junction
275mm, annular eccentricity index 0.90.1. Mean number of calcified commisures
1.9 1.1, mean number of annular calcium spots 2.31.2. Edwards valve was used in 13
(19.1%), while CoreValve in 55 (80.8%). Mean valve size was 27.12.2 mm. Mean
balloon size was 25.62.3mm. Postdilatation was effective in reducing AR by 1 grade in
42 patients (79%). Effective post dilatation was achieved in 100% of patients with a “post
dilatation balloon diameter/ coronal diameter ratio” 0.85-1.07. Outcome of post dilatation
was not influenced by the annular eccentricity index. AR following postdilatation was
more in patients with heavily calcified annulus. 1 patient (1.5%) had annular tear
following post dilatation. 30 days echocardiographic follow up showed 1.10.9 AR.
Conclusions: Effectiveness of post dilatation is multifactorial and depends mainly on the
proper choice of the balloon size, which in terms depends on the annular coronal diameter
assessed by CT scan. Since commisural calcification and annular eccentricity index don’t
influence the outcome of post dilatation, there is no need for aggressive postdilatation to
reduce AR after valve implantation.
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Background: There is accumulating evidence that up to 20 % of the implanted devices
after TAVI are associated with a significant degree of paravalvular leaks (PVL), but the
clinical impact of PVL is still insufficiently explored.
Methods: A total of 355 patients with severe aortic valvulare stenosis (AVS) were treated
by TAVI (Corevalve n 222, Edwards Sapien n 133). Survival, NT-pro-BNP and the
grade of PVL were quantified up to 12 months after implantation.
Results: Technical success rate was 97 %. Thirty-day mortality was 9.6%. Post-
procedural transvalvular aortic regurgitation was seen only in a minority of cases (5%),
whereas PVL were frequently observed (grade:1	 in 58.2%, 1	2	 in 33.9%,
and 2	 in 7.9%). There was a clear relation-ship between PVL and adverse outcome
(p 0.001). After a transient increase NT-pro-BNP showed a significant decline.
Interestingly, a PVL 2	 was associated with a much higher rise in NT-pro-BNP
compared to the other groups (p 0.01), and a post-procedural increase in NT-pro-BNP
by more than 1640ng/L was associated with a significant increase in rate of death
(p 0.01).
Conclusions: TAVI is an efficient treatment option for high-risk patients with severe
AVS. The incidence of PVL is an inacceptable clinical problem and still insufficiently
recognized. Serial measurement of NT-pro-BNP can be used for risk-stratification in
patients with a significant PVL. In general, PVL graded 2	 is associated with a
dramatically increased 6-month mortality. Therefore, any action to fight against parapros-
thetical regurgitation is highly recommended.
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Background: The logistic European System for Cardiac Operative Risk Evaluation
(logEuroSCORE II) has been introduced to improve prediction of acute mortality in
cardiac surgery. No specific tools exist for evaluation of patients undergoing transcatheter
aortic valve implantation (TAVI). We assessed predictive ability of the logEuroSCORE
II for perioperative mortality after TAVI and compared it to four other systems of
preoperative risk evaluation.
Methods: 300 consecutive patients (age80.77.2years,59.5%female) undergoing TAVI
using Edwards Sapien (XT) devices were entered into a prospective dedicated database.
Preoperative risk stratification was performed using logEuroSCOREs I and II, Society of
Thoracic Surgeons (STS), Ambler and Parsonnet Scores. Validity of scores was assessed
by receiver-operator curves (ROC) and resulting area under the curve (AUC).
Results: Observed 30-day mortality in our sample was 10.7%(32/300). Calculated scores
were: logEuroSCORE I mean22.8%,CI0.21-0.246, logEuroSCORE II mean 7.3%, CI0.064-
0.081, STS mean 8.6%, CI0.077-0.095, Ambler mean 6.3%, CI0.057-0.070, Parsonnet mean
22.5%, CI0.209-0.241. ROC analyses revealed none of the tested systems to possess adequate
predictive value for acute mortality following TAVI: logEuroSCORE I AUC0.57, CI0.45-
0.69, logEuroSCORE II AUC0.58, CI0.47-0.70, STS AUC0.59, CI0.47-0.71, Ambler
AUC0.53, CI0.41-0.65, Parsonnet AUC0.51, CI0.38-0.64. To estimate accuracy (sum of
correct positive and negative predictions), Youden-indices (maximum of sensitivity and
specificity) were calculated and used to determine thresholds for classification of scores as
false/true. Derived accuracy was low, ranging between 34.0%(Ambler) and 55.2%(logEuro-
SCORE II).
Conclusions: None of the tested risk stratification systems including the new logEuro-
SCORE II provided adequate prediction of acute mortality in our large routine TAVI
cohort. Likely, scoring systems derived from classic cardiac surgery databases are
inadequate for risk prediction in TAVI patients. Therefore, specific risk models are needed
for high-risk patients undergoing TAVI. Until these are available, evalutation of
perioperative risk has to rely on interdisciplinary clinical judgment of individual patient
factors.
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Background: Transcatheter valve-in-valve implantation (VinV-TAVI) has emerged as a
potential option in addition to reoperative surgical aortic valve replacement to treat failed
biological heart valve substitutes, however with limited experience. Herein we report the
comprehensive experience of VinV-TAVI in the Nordic countries from May 2008 to
January 2012.
Methods: A total of 49 VinV-TAVIs (45 aortic, 2 mitral and 2 tricuspid) were performed
during this time period in 11 centers. For the aortic VinV:s, the mean age of patients was
80.6 (61-91) years (M 26;F 19) and mean Euroscore, Euroscore II and STS scores were
35.4, 16.3 and 14.6, respectively. The type of failure was stenosis/combined in 58% (mean
and peak aortic valve gradients 77 and 45 mmHg) and regurgitation 42% of cases. The
Sapien/XT® (Edwards Lifesciencies, Irvine, CA) and CoreValve® (Medtronic Inc,
Minneapolis, MN) system was used in 33 and 12 cases, respectively. The access routes
were transapical in 25, transfemoral in 17, transaortic in 2 and subclavian in one case. The
mean follow-up was 10.6 months. The periprocedural and postoperative outcome was
assessed according to the VARC criteria.
Results: There was no intraoperative mortality. The technical success rate was 95.6%
(one 2nd valve implantation, one conversion to open surgery). All-cause 30-day mortality
was 4.4% (one cardiac-related, one aspiration pneumonia). Major complications within 30
days were sroke in 2.2%, periprocedural MI in 4.4% and major vascular complication in
2.2% of patients. At 1 month all but one patient had either no or mild paravalvular leaks
with mean and peak valve gradients of 17(4-38) and 30(7-68) mmHg, respectively. The
mean gradient was  20 mmHg in 17% of patients; that remained unchanged at 12
months. The 1-year survival was 85.2%.
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Conclusions: VinV –TAVI is widely performed, albeit in small numbers, in majority of
centers in the Nordic countries. The short-term results are excellent on this high-risk
patient population, demonstrating a low incidence of procedure-related complications.
However, a number of patients are left with suboptimal systolic valve performance with
unknown long-term effects, warranting a close surveillance after VinV-TAVI.
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Background: The last few years, transcatheter aortic valve implantation (TAVI) has
evolved as a good alternative treatment for patients rejected or with high risk for aortic
valve replacement (AVR). Very few studies report reasons for rejection for TAVI and the
outcome of these rejected patients. The purpose of this study is to investigate the reasons
for rejection for TAVI and compare survival between rejected and treated patients.
Methods: In this retrospective single center study patients referred for TAVI between
October 2007 and September 2011 are included. Reasons for rejection for TAVI were
collected and survival was compared for conservative treatment with transfemoral or
transapical TAVI and surgical AVR.
Results: We included 374 patients(mean age 81 years, 49% male); 150 patients were
rejected for TAVI. Reasons for rejection were: multiple comorbidities (24%), surgical
candidate (14%), other heart disorders (poor left ventricular function and/or other valve
abnormalities) (10%), asymptomatic or no severe aortic stenosis (7%), poor renal
function, malignancy, severely impaired lung function, cognitive reasons, poor peripheral
vessels and extreme high age. A total of 160 patients were treated by transfemoral TAVI
and 64 patients by transapical TAVI. Patients treated by TAVI or surgically had a
significant better 2-year survival than patients treated conservatively.
Conclusions: There are many reasons for rejection for TAVI, but the main reason was
multiple comorbidities. Patients with symptomatic severe aortic valve stenosis treated by
TAVI or surgical have a better survival than patients treated conservative.
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Background: Severe aortic regurgitation (AR), when intervention is required, is
managed by surgical aortic valve replacement (SAVR). TAVR could be a valid “off label”
option to treat severe AR for patients unsuitable for SAVR due to their high surgical risk.
However, in severe AR, large aortic annulus and poor aortic valve calcifications made
challenging TAVR. We hereby report our single centre experience of 8 cases (see Table)
of AR in which surgical correction was excluded because of high predicted operative
mortality. These cases were treated with TAVR using Medtronic CoreValve prostesis.
Total of patients 8
Age y (mean) 81
NYHA class III-IV pre TAVR % I00
L-Euroscore % 31
2 valve requirement (valve-in-valve) 0%
Ao regurgitation post TAVR  2 20%
New permanent PM implantation % 40
6 month mortality none
Methods: In all cases an oversizing prosthesis was used. Pre-dilation with balloon
valvuloplasty was never performed. During valve deployment a rapid (180 bpm) pacing
was used in order to prevent valve ejection.
Results: In our patients there were no peri-procedural major complications (stroke, major
bleeding). A new permanent PM implantation was necessary in 3 pts. At the 30-days and
6-month follow up we observed an improved functional capacity and no death.
Conclusions: TAVR in AR remains an off-label application needing further study.
However in selected cases may be considered as a valid option to treat severe AR in
patients unsuitable for SAVR.
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Background: TAVR has become a standard therapy for patients with severe aortic
stenosis considered to be inoperable or at very high risk for surgery. For both types of
currently available prostheses (the selfexpanding CoreValve (Medtronic, Minneapolis,
MN) and the ballon-expandable Edwards–Sapien XT (Edwards Lifesciences, Irvine, CA))
the standard procedure includes a balloon predilation as part of the procedure before
implanting the actual device. Although predilation of the calcified valve may facilitate
device placement, it bears a risk of stroke and conduction disturbances, two major
drawbacks of this procedure.
Methods: We performed a prospective study in 74 consecutive patients to investigate the
feasibility and procedural results of direct implantation of the selfexpanding Medtronic
CoreValve prosthesis without predilation.
Results: A total of 74 consecutive patients implanted with a CoreValve aortic biopros-
thesis were included in our study. Successful implantation was achieved in 73 (98.6%) of
the patients. Postdilation was necessary in 27% of the cases. Evaluation of outcome after
30 days showed a stroke/TIA rate of 2.7% with a 1.3% rate of major stroke. At 30 days
need for permanent pacemaker insertion post TAVR was 21.7% and overall mortality was
4.1 %. Procedural results showed an average implantation depth of 5.93.2 mm below
the annulus line and a rate of postprocedural aortic regurgitation  grade 2 of 1.4%.
Conclusions: Direct implantation of the CoreValve selfexpanding aortic bioprosthesis
without predilation is feasible and may be a safe alternative to the standard procedure
using predilation. Procedural results showed a low number of strokes and need for
postinterventional pacemaker implantation. Prospective studies should be performed to
compare both techniques of implantation with respect to periprocedural stroke rates and
need for pacemaker implantation.
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Background: Elevated concentrations of troponin T (cTnT) have prognostic impact in
patients with aortic stenosis. For patients with high risk for conventional aortic valve
replacement, transcatheter aortic valve replacement (TAVR) has become an established
therapeutic option.
Methods: We conducted a retrospective analysis in 201 consecutive patients scheduled
for transfemoral TAVR and analyzed predictors, kinetics and prognostic values of pre-
and postinterventional troponin T levels by using a high sensitive troponin T assay (Roche
Diagnostics).
Results: Patients with severe aortic stenosis had significantly elevated levels of cTnT
detectable before TAVR. Postinterventional cTnT levels rose significantly about seven
fold after transfemoral TAVR. Cardiac cTnT levels were highest at day 3 after TAVR
(204 11 pg/ml (mean SEM) compared to 43 3.1 pg/ml before TAVR) and steadily
declined thereafter. Baseline renal function (p0.011), the duration of intraprocedural
rapid pacing (P0.0012) left ventricular mass (p0.01) and baseline cTnT (p0.0001)
values were related to postinterventional cTnT release. Interestingly, Kaplan-Meier
survival curve analysis revealed, that although cTnT levels were not predictive for
shortterm mortality, preinterventional as well as postinterventional peak cTnT showed
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